Home » Contraceptive Patch Should Stay, But With Stronger Labeling, REMS
Contraceptive Patch Should Stay, But With Stronger Labeling, REMS
A joint FDA advisory panel is recommending Janssen Pharmaceuticals’ Ortho Evra transdermal contraceptive patch remain on the market as its benefits outweigh the risk of blood clots for most women. However, new labeling is needed to clearly reflect the risk-benefit profile, it says.
Devices & Diagnostics Letter
Devices & Diagnostics Letter
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May